STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2]
80% of Respondents Report InsufficientDigitalisation; Progress Stalled by Technology Knowledge and Funding Gaps
Celebrate Raya with daily free shipping,exciting deals and cashback giveaways from Taobao KUALA LUMPUR,Malaysia,March 4,2025--Taobao Malaysia is ushering in its first-ever sales campaign dedicated to
BARCELONA,Spain,March 4,2025-- TCL,a pioneer in display across feature-rich smartphones,tablets,and connected devices,has showcased its commitment to user-centric innovation by unveiling a comprehensi
BANGKOK,March 4,2025-- S Hotels and ResortsPCL(SET: SHR),the global hospitality company announced its 2024 financial results,revealing a record revenue of 10.352 billion baht,reflecting the ongoing ex
MANILA,Philippines,March 4,2025-- TotalEnergies ENEOS successfully commissioned a 1.9 megawatt-peak (MWp) solar rooftop photovoltaic (PV) system in collaboration with SteelAsia Manufacturing Corporat
